News AbbVie joins BMS in taking a hard line on UK drug pricing AbbVie has said it may not launch its ovarian cancer therapy Elahere in the UK if a viable NHS price cannot be agreed with NICE.
News AbbVie loses bid to block 340B law in Mississippi Battle lines are being drawn on 340B rebates as AbbVie loses a bid to block a Mississippi law seeking to retain discounts for contract pharmacies.
News AbbVie lifted by lengthy delay to generics of Rinvoq Shares in AbbVie were lifted today after the company revealed that it has settled patent litigation with generic drugmakers on blockbuster Rinvoq.
News Rumour partly confirmed as AbbVie acquires Gilgamesh drug Reports of AbbVie's interest in Gilgamesh Pharma were true, as the companies have agreed a $1.2bn acquisition deal for a psychedelic depression drug.
News Is AbbVie planning an epic Gilgamesh takeover? AbbVie could be heading for its second acquisition in the space of a month, as rumours emerge of a $1bn bid for psychiatric drug developer Gilgamesh.
News AbbVie files to move Venclexta combo into the CLL front line AbbVie has filed for FDA approval of a new front-line therapy for chronic lymphocytic leukaemia that it thinks could be 'practice changing."
Digital FH25: Jessica DaMassa on hosting, hype, and health innovatio... In a new episode of our limited Frontiers Health series of the pharmaphorum podcast, we speak with WTF Health founder and event emcee, Jessica DaMassa
Digital Sponsored Tracking studies get smarter: AI meets human intelligence Having a continuous pulse on brand health is essential for pharmaceutical companies to inform strategic decisions and establish Key Performance Indicators (KPIs) in an ever-changing market
